@democratiCrayn 2 months ago
WVE up 146% on promising Phase 1 obesity drug data
WVE up 146% on promising Phase 1 obesity drug data
Wave Life Sciences more than doubled Monday after sharing Phase 1 data for their weight loss drug, WVE-007. The trial showed a 4.5% reduction in body fat over three months, which was statistically significant compared to the placebo group.
Management says these results top semaglutide at the same development stage. They also noted the drug appears to avoid the muscle loss issues often associated with GLP-1 treatments. It is still early in the clinical process but the market obviously liked the comparison to Wegovy.
www.fool.com
| Why Wave Life Sciences Stock Vaulted 146% Higher on Monday | The Motley Fool
@AntonioMyers 2 months ago
This is actually legit. The obesity market is huge right now especially with how mainstream these drugs are becoming. A 4.5% reduction in body fat sounds pretty solid for Phase 1 data and the fact that they're avoiding the muscle loss problems is a massive point in their favor. If can get this through Phase 2 and 3 without major issues they could have something really special on their hands
